妇科医生与产业界:阳光之下无秘密
生殖医学领域创新与营销相伴,医生与药械厂商之间的财务关系引发争议。本文建议生殖医学专家公开从产业界获得的财务收益,产业资助研究款项应归入机构基金而非直接付给研究者,并应公开款项来源与用途。
要点
- 生殖医学专家应公开从产业界获得的财务收益,因其可能影响研究结果和患者治疗。
- 产业资助研究款项应集中归入机构基金,不直接支付给研究者,并公开来源与用途。
- 医学社团产业赞助应保持最低限度并在网站和项目手册中定量申报,学术会议赞助不得含主办教育研讨会或指定讲者的权利。
核心结论
- 生殖医学专家应透明公开从产业界获得的财务收益,因其可能影响研究结果和所提供治疗。
- 作者建议产业资助研究款项应归入机构基金而非直接付给研究者,并公开款项来源与用途。
- 作者建议医学社团的产业赞助应保持最低限度并定量申报,学术会议赞助不得含主办教育研讨会或指定讲者的权利。
- 作者建议所有讲者应在会议上申报利益冲突,指南工作组应在会前要求全体成员申报财务利益冲突并排除或限制有冲突成员。
- 作者建议政府当局不应允许不符合上述政策的教育活动获得继续医学教育学分,并重申医学期刊作为识别科学守门人的关键作用。
研究设计与样本
- 本文为针对生殖医学领域医生与产业界财务关系的评论文章,未报告系统检索范围或样本量。
主要发现
- 生殖医学领域创新伴随营销和对潜在处方医生及使用者的接触,医生与药械厂商的财务关系在过去十年被广泛讨论。
- 医生与产业界的关系一方面可能通过促进改进治疗产生协同效应,另一方面产业界支付和其他利益可能微妙地将合作主要目标从患者健康转向医生与产业界的互惠。
- 不孕患者可被视为脆弱人群,因其面临寻求为人父母的多重挑战、理解复杂且昂贵且并非普遍成功的生育治疗,同时因年龄不断增长而承受压力,他们有权获得最具成本效益的治疗。
临床怎么用
- 作者建议生殖医学专家应透明公开从产业界获得的财务收益,因其可能影响研究结果和所提供治疗。
- 作者建议产业资助研究款项应集中归入机构基金,不直接支付给研究者,并公开款项来源与用途。
- 作者建议医学社团及其教育活动的产业赞助应保持最低限度,并在社团网站和科学项目手册中定量申报。
- 作者建议学术会议的产业赞助不得包含在会议项目中主办教育研讨会或指定讲者的权利,所有讲者应在会议上申报利益冲突。
- 作者建议指南工作组应在会前要求全体成员申报财务利益冲突并排除或限制有冲突成员,政府当局不应允许不符合上述政策的教育活动获得继续医学教育学分。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The field of reproductive medicine is known for its innovations, and where there is innovation there is marketing and engagement with the doctors who are potential prescribers and users of those innovations. Financial connections between drug and device manufacturers with doctors have been extensively debated over the past decade. On one hand, relationships between doctors and industry could be considered synergistic by allowing the development of improved treatments. On the other hand, payment (and other benefits) from industry to doctors may subtly shift the main objective of the collaboration from patients' health to mutual benefits for both doctors and industry. Fertility patients can be considered 'vulnerable' as they face the multiple challenges of seeking to be parents, understanding complex and expensive fertility treatments that are by no means universally successful, and at the same time are under pressure because of their ever-increasing age. They are entitled to receive the most cost-effective treatments. We suggest that specialists in the field of reproductive medicine should be transparent about the receipt of financial benefits, including funding from industry, as it may be influencing both research outcomes and treatments that patients are offered. We also recommend that payments arising from industry-sponsored research should be centralized in institutional funds and not paid directly to researchers. And there should be transparency about the source and the purpose of the payment. Industry sponsorship of medical societies and their educational events should be kept to a minimum and declared quantitatively in societies' websites and scientific programme brochures. Industry sponsorship of scientific meetings should not include the right to host educational symposia or speakers within the programme. All speakers should declare their conflicts of interest (COIs) at their meetings. Guideline groups should require all members to declare their financial COIs before meeting and exclude or limit those members with COI. Governmental authorities should not allow continuing medical education credits to those educational events not complying with the above policies. The crucial role of medical journals as 'gatekeepers' for identifying 'science' must be reaffirmed.
引用
- Farquhar CM, Vercellini P, Marjoribanks J, et al. Gynaecologists and industry: ain't no sunshine. Hum Reprod. 2017. PMID: 28854593. doi:10.1093/humrep/dex228
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。